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Suicide gene therapy using the herpes simplex virus thymidine 
kinase/ganciclovir (HSV-tk/GCV) system combined with monocyte chemoattractant 
protein-1 (MCP-1) provides significant antitumor efficacy. The current study was 
designed to evaluate the antitumor immunity of a newly developed membrane-bound 
form of MCP-1 (mMCP-1) in an immunocompetent mouse model of hepatocellular 
carcinoma (HCC). A recombinant adenovirus vector (rAd) harboring the human MCP-1 
gene and the membrane-spanning domain of the CX3CL1 gene was used. Large 
amounts of MCP-1 protein were expressed and accumulated on the tumor cell surface. 
The growth of subcutaneous tumors was markedly suppressed when tumors were 
treated with mMCP-1, as compared to soluble MCP-1, in combination with the 
HSV-tk/GCV system (P <0.01). The numbers of Mac-1-, CD4- and CD8a-positive cells 
were significantly higher in tumor tissues (P <0.05), and tumor necrosis factor (TNF) 
mRNA expression levels with mMCP-1 were almost 5-fold higher than those with 
soluble MCP-1. These results indicate that the delivery of the mMCP-1 gene greatly 
enhanced antitumor effects following the apoptotic stimuli by promoting the 
recruitment and activation of macrophages and T lymphocytes, suggesting a novel 
strategy of immune-based gene therapy in the treatment of patients with HCC. 
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 In spite of the recent development of locoregional treatments for hepatocellular 
carcinoma (HCC), the frequency of tumor recurrence remains high, probably because of 
insufficient therapeutic effects and the multicentric development of HCC in cirrhotic 
liver (1-3). Non-surgical treatments of HCC, such as radiofrequency ablation, 
transcatheter arterial embolization, and transcatheter arterial chemotherapy induce 
apoptosis of HCC cells, but these treatments do not enhance antitumoral immunity 
sufficiently. Thus, gene therapy aimed at enhancing antitumor immune responses may 
be a promising approach to prevent HCC recurrence, when it is combined with 
non-surgical maneuvers. 
 We previously reported that monocyte chemoattractant protein-1 (MCP-1) gene 
delivery using recombinant adenovirus vector (rAd) in vivo can enhance the efficacy of 
suicide gene therapy consisting of the delivery of rAd containing herpes simplex virus 
thymidine kinase (HSV-tk) and ganciclovir in models of HCC (4, 5) and colon cancer 
(6). We further demonstrated that the antitumor effects depended on the activation of 
macrophages (4, 5). The adenovirus-specific spatial and temporal expression pattern 
may result in the production of the transgene for a limited time (7). Mirroring these 
characteristics, the adenovirus vector-mediated delivery of MCP-1 gene alone was not 
sufficient to reduce tumor growth (5). In order to circumvent this bottleneck, sustained 
expression of MCP-1 at the tumor site may be required to enhance the efficacy of the 
gene therapy using MCP-1 gene.  
 Systemic or local administration of cytokines has been used to enhance the 
antitumor immune response induced by many cancer vaccines. However, the systemic 
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administration of cytokines resulted in unwanted side effects. Recently, tumor therapy 
that uses a membrane-bound form of cytokine was developed to reduce the side-effects 
of cytokine in the systemic circulation. These experiments revealed that the 
membrane-bound form of cytokine not only reduced the side-effects but enhanced the 
anti-tumor effects by prolonging the half-life of cytokines in the tumor 
microenvironment (8).  
 These observations prompted us to design the adenovirus vector driving the 
expression of membrane-bound form of MCP-1 (mMCP-1) and to evaluate its antitumor 
effects in a model of HCC. We demonstrated that the delivery of mMCP-1 gene 




Materials and Methods 
 
Recombinant adenovirus vectors 
 Ad-mMCP1 (Fig. 1a) harboring the human MCP-1 gene and the 
membrane-spanning domain of the CX3CL1 gene driven by the human cytomegalovirus 
immediate early promoter/enhancer (CMV IE) promoter was prepared, purified, and 
titrated according to the protocols supplied by the manufacturer (Takara, Tokyo, Japan). 
The human MCP-1/CX3CL1 (Fractalkine) chimera was designed as follows. DNA 
encoding a fragment of human CX3CL1 spanning the intracellular, transmembrane and 
partial extracellular region was amplified from the full-length CX3CL1 cDNA by PCR 
with the following primers (5'-GCGAGCTCGGGTACCTTCGAGAAGCAGATCG and 
5'-GCGAATTCAGATTGTCACACGGGCACAGG). SacI, KpnI and EcoRI restriction 
enzyme sites were added at the 5' and 3' ends of this fragment. MCP-1 was also 
amplified by PCR with the following primers 
(5'-GCGAGCTCGCCAGCATGAAAGTCTCTGCCG and 
5'-GCGGTACCAGTCTTCGGAGTTTGGGTTTGC). SacI and KpnI restriction 
enzyme sites were added at the 5' and 3' ends of this fragment. The CX3CL1 and 
MCP-1 DNA fragments were digested with restriction enzymes by coligation into the 
SacI and EcoRI sites of pSTBlue-1 (Novagen, Darmstadt, Germany), generating 
pSTBlue-1-mMCP1. Then, pSTBlue-1-mMCP1 was digested by NotI and BamHI 
restriction enzymes, and the fragment was inserted into the pShuttle Vector (Clontech 
Laboratories, Mountain View, CA) under the control of CMV IE promoter, generating 
pShuttle-mMCP-1. pShuttle-mMCP-1 was digested with PI-SceI/I-CeuI (New England 
Biolabs. Hitchin, UK), and the purified product was ligated with Adeno-X genome 
6 
 
DNA, containing nearly the full length of the adenovirus type 5 genome lacking the E1 
and E3 regions, to generate pAd.mMCP1. Subsequently, Ad-mMCP1 was generated by 
transfecting 293 cells with pAd.mMCP1, which was linearized with PacI, as described 
in the manual. Ad-sMCP1 (which expresses sMCP1), Ad-lacZ (which expresses 
beta-galactosidase (lacZ)) and Ad-tk (which expresses HSV-tk) were constructed as 
previously described and propagated in 293 cells (Fig. 1b, c, d ) (9). The rAds were 
purified on a cesium gradient, and the titer of rAd was determined by the 50% tissue 
culture infectious dose (TCID50) method (10). 
 
Cell lines and culture 
The mouse HCC cell lines (BNL 1NG A2, BNL 1ME A.7R.1, MM45T.Li and Hepa 
1-6) and the colon cancer cell line Colon 26 were used in these experiments. Cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM) (Gibco, Long Island, NY) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco). 
 
Enzyme-linked immunosorbent assay (ELISA) for MCP-1 
Aliquots of 1×105 HCC lines (BNL 1NG A2, BNL 1ME A.7R.1, MM45T.Li and Hepa 
1-6) and the colon cancer cell line, Colon 26 clone 20, were seeded in 1.0 ml of culture 
media in a 6-well tissue culture plate. After 24 hours, the cells were infected with 
Ad-mMCP1, Ad-sMCP1 and Ad-lacZ at various multiplicities of infection (MOI). After 
48 hours, the cells were harvested and sonicated to obtain the membrane fractions, and 
the media was collected from each well. Tumor tissues were resected on day 1 after s.c. 
injection of 5 × 106 MM45T.Li cells infected with indicated rAds (MOI 50) as 
described below. Tumor tissues were washed with PBS and sonicated to obtain the 
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membrane fractions. The concentration of MCP-1 was determined by ELISA as 
described previously (11). Briefly, each well of a 96-well microtiter plate was coated 
with monoclonal anti-human MCP-1 antibody (ME61; 1 mg/ml) overnight at 41oC. 
After washing, the plates were blocked by incubation with PBS containing 1% bovine 
serum albumin (BSA) for 1 hour at 37oC. Diluted sample media was added, and the 
plate was then incubated for 2 hours at 37oC. Following incubation, the plates were 
washed and incubated with rabbit anti-MCP-1 antibody (1 mg/ml), followed by alkaline 
phosphatase-conjugated goat anti-rabbit antibody (1/12,000, Tago, Burlingame, CA), 
each for 2 hours at 37oC. After the plate was washed, aliquots of 1 mg/ml 
p-nitrophenylphosphate (Sigma, St Louis, MO) in 1M diethanolamine (Sigma) (pH 9.8) 
supplemented with 0.5 mM MgCl2 were added to the wells, and the plate was incubated 
for 40 minutes at room temperature. After the addition of 1M NaOH, the optical density 
(405 nm wavelength-OD405) was assessed by using an ELISA plate reader (MTP-120; 
Corona Electric, Ibaragi, Japan). 
 
In vitro chemotaxis assay 
In vitro migration assays were performed with the QCM chemotaxis cell migration 
assay (5 m, Chemicon International, Temecula, CA) according to the manufacturer's 
instructions. Briefly, 7.5×104 splenocytes were resuspended in 100 l of RPMI1640 
containing 5% BSA and loaded into the upper well of a transwell chamber. The lower 
wells were filled with 150 l of supernatant from MM45T.Li cells that were harvested 
48 hours after infection with rAds. The cells were incubated for 4 hours at 37oC in a 
humidified, 5% CO2 atmosphere. The migrated cells were lysed and detected by the 
CyQuant GR dye (Molecular Probes, Eugene, OR), and fluorescence was read at an 
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excitation wavelength of 490 nm and an emission wavelength of 520 nm in a 
fluorescence microplate reader (Thermo Scientific Fluoroskan Ascent FL, Thermo 
Fisher Scientific Oy, Vantaa, Finland).  
 
In vitro proliferation assay  
In vitro proliferation assays were performed with the CellTiter 96 Aqueous 
Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA) according to 
the manufacturer's instructions. Briefly, aliquots of 1 × 104 MM45T.Li cells that were 
harvested 24 hours after infection with rAds were seeded in a 96-well tissue culture 
plate and incubated for 24hours. MTS 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetraz
olium] solution was added and incubated for 2hours, and the absorbance at 490 nm was 
measured by using an ELISA plate reader (MTP-120; Corona Electric, Ibaragi, Japan). 
 
Animal studies 
The following investigations were performed in accordance with the guidelines of our 
Institutional Animal Care and Use Committee. Six-week-old immunocompetent female 
BALB/c-jcl mice (CLEA Japan, Tokyo, Japan) were injected subcutaneously on both 
sides of the flank on day 0 with 3 × 105 MM45T.Li cells infected with each rAd at an in 
vitro MOI of 5. For the next 5 days (days 1–5), mice received 75 mg/kg of 
intraperitoneally administered ganciclovir (GCV; Tanabe Pharmaceutical Drug, Tokyo, 
Japan). In some series of experiment, 1 μg of the recombinant human MCP-1 in 200 μL 
of PBS containing 1% bovine serum albumin (BSA-PBS) were injected 
intraperitoneally as previously described (12) from days 0 to 2 (3 consecutive days) in 
9 
 
the group of the tumor cells transduced with Ad-lacZ on HSV-tk/GCV suicide therapy. 
Tumor sizes were measured every 3 days, and tumor volumes were calculated according 
to the formula (longest diameter)/ (shortest diameter) 2 / 2. 
 
Immunohistochemical analysis 
Tumor tissues and spleens were resected on day 10. The tissue samples were embedded 
in OCT compound (Sakura Finetek, Toorrance, CA, USA) and snap frozen in liquid 
nitrogen. Cryostat sections of the frozen tissues were fixed with 4% paraformaldehyde 
(PFA) in PBS, followed by washing once with distilled water for 5 min and 3 times with 
PBS for 5 min. To avoid nonspecific staining, avidin and biotin in the tissues were 
blocked by using a blocking kit (Vector Laboratories, Burlingame, CA, USA). 
The tissue sections were subsequently stained with rat anti-mouse CD4 Ab, rat 
anti-mouse CD8a Ab, rat anti-mouse CD11b Ab (BD Biosciences, San Diego, CA, 
USA), or monoclonal mouse anti-human MCP1 Ab (R&D systems, Minneapolis, MN, 
USA) overnight at 4°C. Isotype controls were also used. Then, the slides were incubated 
for 0.5 hours at room temperature with biotinylated polyclonal rabbit anti-rat IgG (Dako 
Cytomation, Tokyo, Japan), or the antibodies in the M.O.M. immunodetection kit to 
detect mouse primary antibodies on mouse tissues (Vector Laboratories). The reactions 
were visualized by using a VectaStain ABC standard kit (Vector Laboratories), 
followed by counterstaining with hematoxylin. The positive cells were counted in 10 
randomly chosen fields at 400-fold magnification by an examiner without any prior 
knowledge of the experimental procedures. 
 
Quantitative real-time RT-PCR 
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Total RNA was extracted from tumor tissues resected on day 10 using an RNeasy Mini 
kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. After 
treating the RNA preparations with ribonuclease-free deoxyribonuclease (DNase) I 
(Qiagen, Hilden, Germany) to remove residual DNA, cDNA was synthesized as 
described previously (19). Quantitative real-time PCR was performed on a StepOne™ 
real-time PCR system (Applied Biosystems, Foster City, CA) by using the comparative 
CT quantification method. TaqMan® Gene Expression Assays (Applied Biosystems, 
Foster City, CA) containing specific primers (assay ID: TNF, Mm00443258_m1; 
GAPDH, Mm99999915_g1), TaqMan® MGB probe (FAM™ dye-labeled), and 
TaqMan® Fast Universal PCR Master Mix were used with 10 ng cDNA to quantify the 
expression levels of TNF. Reactions were performed for 20 s at 95°C followed by 40 
cycles of 1 s at 95°C and 20 s at 60°C. GAPDH was amplified as an internal control, 
and the GAPDH CT values were subtracted from CT values of the target genes (CT). The 
ΔCT values of tumors after immune gene therapy with both the suicide gene (HSV-tk 
system) and rAds were compared respectively. 
 
Flow cytometry 
MM45T.Li cells transfected with rAds were resuspended in PBS containing 1% BSA 
and 0.1% sodium azide and incubated for 30 min on ice with PE-conjugated rat 
anti-human MCP-1 (BD Pharmingen, San Diego, CA). The cells were washed, 
resuspended in PBS, and analyzed in a FACScan with CellQuest software 
(FACSCalibur, BD Biosciences, San Jose, CA). 
 
Depletion of macrophages/monocytes 
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Clodronate liposome was prepared and systemic depletion of monocytes/macrophages 
was performed as previously described (13, 14). Mice were intraperitoneally injected 
with 200 μL of clodronate liposome five times: days −2, 0, 3, 6, and 10 after tumor 
injection. PBS-clodronate was given in the same manner as a negative control. 
Depletion of CD11c-negative monocytes in blood was confirmed by flow cytometry 
after injection of clodronate liposome. 
 
Statistical analysis 
Mean and SD or SE were calculated for the obtained data. The statistical significance of 






In vitro and in vivo MCP-1 production by cells infected with recombinant 
adenoviruses.  
When various tumor cells were infected with either Ad-mMCP1 or Ad-sMCP1 
at a MOI of 10, the cells did not show any signs of cell death (data not shown). Both 
types of adenoviruses induced the secretion of human MCP-1 into the supernatants to 
similar levels in all the cell lines that we examined (Fig. 2a). On the contrary, MCP-1 
contents in the membrane fractions were higher in the cells infected with Ad-mMCP-1 
than in those with Ad-sMCP1 (Fig. 2a). The proportion of MCP-1-positive cells were 
progressively augmented in MM45T.Li cells as the MOIs of the used Ad-mMCP1 were 
increased (Fig. 2b). In contract, MCP-1-positive cells were not detected in tumor cells 
infected with Ad-sMCP1 and Ad-lacZ, even when the cells were infected with either 
vector at a MOI of 100 (Fig. 2b). Thus, Ad-mMCP1 infection can in vitro drive human 
MCP-1 expression on the cell surface as well as its secretion into the culture medium. 
These results indicate that large amounts of MCP-1 protein were expressed and 
accumulated on the tumor cell surface when tumor cells were infected with Ad-mMCP1 
as compared to Ad-sMCP1 in vitro. In order to define the biological functions of 
secreted human MCP-1 protein, we examined the migratory capacity of splenocytes to 
the culture supernatants obtained 24 hours after the infection. The supernatants from 
either Ad-mMCP1- or Ad-sMCP1-infected cells enhanced the transmigration of splenic 
lymphocytes to similar extents, compared to those from Ad-lacZ-infected cells (Fig. 2c). 
These results indicated that biologically active human MCP-1 was secreted into the 
culture supernatants. 
 
Proliferation of tumor cells infected with rAds in vitro and in vivo. 
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To quantify the proliferation of tumor cells infected with rAds, the MTS assay 
was performed 24 hours after infection. The optical absorbance at 490 nm of tumor cells 
did not change in the presence or absence of rAd infection (Fig. 3a). Next, tumor cells 
infected with rAds (MOI 10) ex vivo were transferred subcutaneously in syngeneic 
wild-type mice, and tumor development was monitored (Fig. 3b). Tumor cells infected 
with Ad-mMCP1 and Ad-sMCP1 showed similar growth rates to tumor cells infected 
with Ad-lacZ. These results indicate that infection with the rAds used in this study did 
not affect the proliferation of tumor cells in vitro and in vivo and that the delivery of 
mMCP-1 did not display antitumor activity when used alone. In addition, the levels of 
MCP-1 expression were confirmed immunohistochemically in the subcutaneous tumor 
tissues (Fig. 3c). MCP-1-positive tumor cells were detected in tumor tissues infected 
with Ad-mMCP1, however the cells were negative for MCP-1 staining in tissues 
infected with Ad-sMCP1 and Ad-lacZ. Moreover, larger amounts of MCP-1 were 
detected in the tumor tissues of the mice treated with Ad-mMCP1 than in those with 
Ad-sMCP1 (Fig. 3d). The data indicated that large amounts of MCP-1 protein were 
expressed and accumulated on the tumor cell surface when the tumor cells were infected 
with Ad-mMCP1 in vivo. 
 
Potentiation of HSV-tk/GCV suicide therapy by co-infection with Ad-mMCP1. 
 We previously demonstrated that the gene delivery of Ad-sMCP1 enhanced the 
antitumor effects of the HSV-tk/GCV system (4-6, 15, 16). Hence, we compared the 
effects of Ad-mMCP1- and Ad-sMCP1-infection on HSV-tk/GCV suicide therapy. 
When MM45T.Li cells were co-infected with Ad-tk and Ad-lacZ and received GCV, 
tumor growth was delayed marginally but not significantly (Fig. 4a). Co-infection with 
Ad-tk and Ad-sMCP1 retarded tumor growth significantly after GCV treatment. 
Moreover, tumor growth was almost abrogated by the combination of co-infection with 
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Ad-tk and Ad-mMCP1 and GCV treatment. To address whether the antitumor effects 
could be induced not only by the gene delivery using Ad vector but also by the 
administration of recombinant protein, we gave intraperitoneally recombinant MCP-1 
(rMCP-1) to the animals, which were injected with tumor cells, treated with Ad-lacZ 
and Ad-tk. The systemic administration of rMCP-1 rather enhanced tumor growth (Fig. 
4b). Because we previously demonstrated that MCP-1 can promote tumor growth in a 
context-dependent manner by recruiting macrophages, which can secrete angiogenic 
factor, vascular endothelial growth factor (VEGF) (15, 17), systemic MCP-1 injection 
may promote tumor growth by its pro-angiogenic activities.  
 
Recruitment and activation of macrophages and T lymphocytes in tumor tissues. 
GCV treatment following co-infection with Ad-lacZ and Ad-tk failed to 
increase the intratumoral numbers of Mac-1-positive macrophages, CD4-positive 
lymphocytes, and CD8-positve lymphocytes, compared with GCV treatment following 
Ad-lacZ infection (Fig. 5a, b). GCV administration following co-infection with 
Ad-sMCP1 and Ad-tk increased the intratumoral Mac-1-positive macrophage, 
CD4-positive lymphocyte, and CD8-positve lymphocyte numbers (Fig. 5a, b). The 
increases were further enhanced by GCV treatment following co-infection with 
Ad-mMCP1 and Ad-tk (Fig. 5a, b). Moreover, intratumoral mRNA expression of TNF, 
a known macrophage and T lymphocyte secretagogue, was markedly enhanced in 
tumors co-infected with Ad-mMCP1, compared with those with Ad-sMCP1 plus Ad-tk. 
To evaluate the functional contribution of intratumoral immune cells, we depleted 
CD11c-negative monocytes/macrophages by intraperitoneal administration of 
clodronate liposome (CL) in the current mouse model. The 
monocyte/macrophage-depleted mice developed larger tumor than those treated with 
PBS liposome (Fig. 5d), indicating that monocytes/macrophages were critically 
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involved in the suppression of tumor growth by Ad-mMCP1. Collectively, these data 
demonstrate that the delivery of mMCP-1 promoted the recruitment and activation of 
macrophages and T lymphocytes in tumor tissues, presumably leading to the beneficial 





 We have proposed a strategy for improving the efficacy of suicide gene-based 
gene therapy by the combined heterochronic administration of HSV-tk and MCP-1 
genes (4-6, 15-17). In the current study, we generated recombinant adenovirus 
Ad-mMCP1 expressing a fusion protein containing the human MCP-1 cDNA fused with 
the membrane-spanning domain of fractalkine/CX3CL1, in order to drive more efficient 
and sessile expression of MCP-1. Ad-mMCP1 infection did not affect the proliferation 
of MM45T.Li tumor cells in vitro or in vivo, by itself. Of interest is that Ad-mMCP1 
infection pontentiated HSV-tk/GCV suicide therapy more efficiently than Ad-sMCP1. 
Moreover, Ad-mMCP1-mediated antitumor effects were associated with the recruitment 
and activation of macrophages and T lymphocytes in tumor tissues. Collectively, the 
delivery of membrane-bound MCP1 gene can augment antitumor effects caused by the 
HSV-tk/GCV system in an immunecompetent mouse model of liver tumor and therefore, 
can be a novel strategy of immune-based gene therapy to prevent tumor proliferation 
and recurrence in patients with HCC. 
 Chimeric membrane-bound cytokine gene expression vectors were generated to 
drive the efficient expression on tumor cell surface and to reduce the severe side effects 
caused by systemic administration of high doses of cytokines. With this maneuver, 
cytokines can be anchored on the cell plasma membrane. As a consequence, a locally 
high concentration of cytokines can be achieved with ease and their in vivo half-life can 
be prolonged in the tumor site. The availability of cytokines on tumor cell surface can 
eventually bring immune cells to the tumor site for better antigen uptake and stimulation, 
thereby inducing antitumor effects at a higher efficiency. Based on these assumptions, 
this type of modified cytokine gene therapy has been reported on IL-2 (18-20), IL-12 
(21), fractalkine (CX3CL1) (22) and TNF (23). Indeed, accumulating evidence revealed 
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that the membrane-bound form of cytokine genes can exhibit more antitumor effects 
than the corresponding soluble ones. Likewise, the current study confirms that the 
membrane-bound form of MCP-1 can attract more immune cells including 
monocytes/macrophages and T lymphocytes, to the tumor sites and can induce the 
expression of TNF. In addition, TNF can activate endothelial cells to express several 
adhesion molecules such as intercellular adhesion molecules (ICAMs), and vascular cell 
adhesion molecules (VCAMs) (24-27). Circulating immune cells can utilize these 
adhesion molecules to effectively transmigrate into the tissues in addition to the direct 
chemotactic activities exerted by MCP-1. 
The effects of MCP-1 on tumor growth was controversial; either destructive 
(28-30) or protective (31, 32) in a context-dependent manner. Likewise, murine colon 
carcinoma cell expressing MCP-1 failed to metastasize when injected into mice (28) 
whereas other carcinoma cells showed enhanced metastasis (31). These discrepancies 
may be explained by the observations reported by Nesbit et al (33). They demonstrated 
that low-level MCP-1 secretion with modest monocyte infiltration resulted in tumor 
formation, whereas high secretion was associated with massive monocyte/macrophage 
infiltration into the tumor mass, leading to its destruction within a few days. Thus, 
systemic MCP-1 administration may not be able to induce massive 
monocyte/macrophage infiltration into tumor mass and may promote tumor mass as we 
observed in the present study. Moreover, we previously revealed that suicide therapy 
can induce tumor cell apoptosis and that apoptotic tumor cells can secrete MCP-1 more 
efficiently, thereby recruiting a massive number of macrophages and retarding tumor 
growth (4). Consistently, we further demonstrated that the delivery of an optimal 
amount of rAd expressing MCP-1 enhanced the antitumor effects of the HSV-tk/GCV 
system in a model of HCC (15, 17). Infection with Ad-mMCP1 can sustain MCP-1 
expression in tumor tissues more efficiently than that with Ad-sMCP1 as evidenced by 
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an immunohistochemical analysis on the infected tumor tissues. The sustained MCP-1 
expression can potentiate suicide gene therapy more efficiently. 
 The present data suggest that the use of Ad-mMCP1 can be promising, but 
several problems remain to be solved before the clinical application. First, subcutaneous 
tumor models of an HCC cell line may not be relevant to HCCs in patients. However, in 
cases of nonsurgical procedures for HCC treatment in patients, such as percutaneous 
radiofrequency ablation therapy (34) and transcatheter arterial chemotherapy (35), 
administration of the current rAd vectors could be easily applied, immediately once the 
standard nonsurgical procedures to ensure tumor cell killing. Moreover, rAd can elicit 
its immunogenicity or cytotoxicity when administered in HCC patients, particularly by 
the use of intraarterial procedures. Actually, the infection of high doses of rAds causes 
severe unexpected side effects (36). However, the delivery of membrane-bound form of 
MCP-1 gene can cause a high and effective concentration at the tumor sites even when 
it is administered at a relatively lower titer and therefore, can evade severe adverse 
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Figure 1. Construct of rAds.  
Under the control of the CMV/IE promoter and the CAG promoter, rAd Ad-mMCP1 (a) 
expressing human MCP-1 and the membrane-spanning domain of fractalkine/CX3CL1 
in sequence, rAd Ad-sMCP1 (b) expressing MCP-1, rAd Ad-lacZ (c) expressing lacZ 
and rAd Ad-tk (d) expressing HSV-tk. Solid lines indicate the rAd genome. An open 
triangle below the rAd genome represents a deletion of adenovirus early regions. 
Arrows show the orientations of the transcription. GpA, rabbit β-globin poly (A) site. 
 
Figure 2. MCP-1 production in tumor cells infected with rAds.  
(a) Concentrations of MCP-1 in the membrane fractions and in the media of hepatoma 
cells (BNL 1NG A.2, BNL 1ME A.7R.1, MM45T.Li and Hepa1-6) and colon cancer 
cells (colon 26 clone 20) infected with rAds at a MOI of 10 were measured by ELISA. 
Each value is the mean SD of triplicate experiments. *, p <0.05 when compared to 
Ad-sMCP1 by the Mann-Whitney’s U test. (b) Surface expression of MCP-1 on 
MM45T.Li cells infected with rAds (Ad-mMCP1, Ad-sMCP1 and Ad-lacZ) at the 
indicated MOIs was assessed by flow cytometry by using PE-conjugated anti-human 
MCP-1 antibody. Histograms represent MCP-1 staining of tumor cells. Numbers 
indicate percentages of MCP-1–positive cells. Surface MCP-1–positive cells were 
detected in 0.08%, 1.2%, 8.1% and 48.0% of MM45T.Li cells infected by Ad-mMCP1 
at MOIs of 0.1, 1, 10 and 100, respectively. The results are representative of three 
independent experiments. (c) The migratory activity of MCP-1 secreted from 
rAd-infected tumor cells. Mouse splenic lymphocytes were loaded into the upper wells 
of transwell chambers, and supernatants of tumor cells infected with rAds at a MOI of 
10 were added to the lower wells. Cells that migrated through 8-m pores to the feeder 
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tray after 4 h incubation were lysed and detected by CyQuant GR dye that exhibits 
enhanced fluorescence upon binding cellular nucleic acids. Each value is the mean SE 
of data from three separate migration chambers. 
 
Figure 3. Proliferation of tumor cells infected with rAds in vitro and in vivo.  
(a) Tumor cell growth after the infection of indicated rAds in vitro. A total of 5 x 105 of 
MM45T.Li cells were infected with the rAds at a MOI of 10 and incubated for 24 h. 
The cell numbers were quantitated by MTS assay. The absorbance was determined at 
490 nm with a microplate reader. Each value is the mean SD of data from triplicate 
experiments. (b) Tumor cell growth after infection of indicated rAds in mice. BALB/c 
mice were subcutaneously injected with 3 x 105 MM45T.Li cells infected with the rAds 
at a MOI of 10 on day 0. Tumor diameters were monitored. Each value is the mean SE. 
(c) Immunohistochemical analysis of subcutaneous tumor tissues 7 days after the 
injection in b. Tissues were stained and visualized by using anti-human MCP-1 Ab and 
ABC methods. MCP-1 expression was seen as brown in the cytoplasm of tumor cells. 
The bar represents 30 m. Original magnification, x 400. (d) Concentrations of MCP-1 
were measured in the s.c. tumor tissues resected on day 1 after injection of 5 x 106 
MM45T.Li cells infected with the indicated rAds at a MOI of 50 by ELISA. Each value 
is the mean SD of duplicate experiments. *, p <0.05 when compared to Ad-sMCP1 by 
the Mann-Whitney’s U test. 
 
Figure 4. Antitumor effects of rAds in vivo.  
(a) BALB/c mice were subcutaneously injected with 3×105 MM45T.Li cells infected 
with rAds Ad-mMCP1+Ad-tk, Ad-sMCP1+Ad-tk, Ad-lacZ+Ad-tk, and Ad-lacZ at a 
MOI of 10 on day 0. Subsequently, 75 mg/kg of GCV was administered for five 
consecutive days (days 2–6). Each value is the mean SE of triplicate experiments. *, p 
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<0.05 when compared to Ad-sMCP1+Ad-tk and **, p <0.01 when compared to 
Ad-lacZ+Ad-tk by the Mann-Whitney’s U test. (b) BALB/c mice were injected with 
MM45T.Li cells and treated as described in the legend to Fig 4a. In Ad-lacZ + Ad-tk + 
recombinant human MCP-1 (rMCP-1) group, the mice were injected with 1 μg of 
rMCP-1 intraperitoneally from days 0 to 2 (3 consecutive days). The mice were injected 
with PBS as controls. Tumor sizes were measured every 3 days. Each value is the mean 
SE. **, p <0.01 when compared to Ad-lacZ+Ad-tk+rMCP-1 by the Mann-Whitney’s U 
test.  
 
Figure 5. Immunohistochemical analysis for Mac-1-, CD4- and CD8a-positive cells 
and expression of TNF mRNA in tumor tissues.  
In the experiment described in the legend to Figure 4, tumors were resected on day 10 
and used for the analyses. (a) Tumor tissues treated with Ad-mMCP1+Ad-tk (a, e and i), 
Ad-sMCP1+Ad-tk (b, f and j), Ad-lacZ+Ad-tk (c, g and k) and Ad-lacZ (d, h and l) 
were stained with anti-Mac-1 antibody (a - d), anti-CD4 antibody (e - h) or anti-CD8a 
antibody (i - l). Positive cells are seen as brown. Original magnification, x 400. (b) 
Quantitative morphometric analysis showing the proportions of positive cells in areas of 
100 tumor cells. Ten high-power (x400) fields of tumor tissue were examined. Results 
are expressed as means per 1000 hepatoma cells. Values are the means SD of triplicate 
experiments. *, p <0.05 when compared to Ad-sMCP1 by the Mann-Whitney’s U test. 
(c) Real-time PCR analysis for TNF mRNA expression in tumor tissues, presented 
relative to GAPDH mRNA. Each value is the mean SD of duplicate experiments. *, p 
<0.05 when compared to Ad-sMCP-1+Ad-tk by the Mann-Whitney U test. (d) BALB/c 
mice were subcutaneously injected with MM45T.Li cells infected with indicated rAds 
and treated as described in the legend to Fig. 4a. In the Ad-mMCP-1 + Ad-tk + 
clodronate liposome (CL) group, mice were injected with 200 μL of CL to deplete 
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monocytes/macrophages as described in Materials and Methods. The mice were injected 
with PBS liposome (PBS) as controls. Tumor sizes were measured every 3 days. Each 
value is the mean SE. *, p <0.05 when compared to Ad-mMCP-1+Ad-tk+PBS by the 
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